La Jolla shares whacked as analysts spotlight disappointing PhIII fine print
Last February, shares of La Jolla Pharmaceutical $LJPC rocketed up on the news that its lead drug hit its primary endpoint in Phase III. At …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
